Please login to the form below

Not currently logged in
Email:
Password:

haemophilia A

This page shows the latest haemophilia A news and features for those working in and with pharma, biotech and healthcare.

Bayer axes 1,250 pharma jobs, with R&D taking the brunt

Bayer axes 1,250 pharma jobs, with R&D taking the brunt

Another 350 pharma jobs will go as a result of a decision not to make use of a recently-completed manufacturing facility for haemophilia treatment factor VIII in Wuppertal. ... In its statement, Bayer said the introduction of a number of new products has

Latest news

  • UniQure skyrockets on haemophilia B gene therapy data UniQure skyrockets on haemophilia B gene therapy data

    Competition with Pfizer and Spark rival heats up. It’s a measure of the anticipation about gene therapy that data positive data in three haemophilia patients caused UniQure shares to close ... It recently recruited the first patient for that study. HOPE

  • AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

    The deal represents a major expansion for Sobi, which is currently focused on rare diseases and haemophilia in Europe (the latter through a licensing deal with Bioverativ), with limited penetration into ... Oelkers concluded: "We see the acquisition as a

  • BioMarin eyes 2019 FDA filing for haemophilia A gene therapy BioMarin eyes 2019 FDA filing for haemophilia A gene therapy

    Rare disease specialist BioMarin is hoping to file for approval its haemophilia A gene therapy valoctocogene roxaparvovec (valrox) in the second half of next year, if its ongoing phase 1/2 ... The California biotech said during an R&D update yesterday

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led ... Another bright spot for Roche was strong

  • Roche gets wider approval for haemophilia drug Hemlibra Roche gets wider approval for haemophilia drug Hemlibra

    Roche says that Hemlibra is the first drug to show an improvement over standard haemophilia A treatment, cutting bleeds by two-thirds (68%) compared to earlier factor VIII prophylaxis. ... a saving over the current costs of treating haemophilia A,

More from news
Approximately 16 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    lives, with the effect lasting a median of 33 months after just one treatment. ... Gilead and Novartis aside, the only companies with a stake in gene therapy with a higher market capitalisation are BioMarin, in pole position to develop a potentially

  • ‘How is your day?’ ‘How is your day?’

    World champion cyclist Alex Dowsett lives with severe haemophilia. He also speaks for ‘How Is Your Day?’. ... plasma. Haemophilia is a condition that can be treated by both laboratory-produced recombinant plasma therapies or medicines made from

  • Deal Watch January 2018

    s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as well as a pipeline of candidates focused on rare blood ... Portfolio/pipeline in haemophilia and other rare

  • The good, the bad and the ugly The good, the bad and the ugly

    However, investors fear that challenges in the $11bn haemophilia market could lead to a slump in the haemophilia business it inherited through the Baxalta purchase. ... These two players will have a comfortable advantage over their nearest rival - Roche (

  • Attracting doctors to low-demand specialties Attracting doctors to low-demand specialties

    Haemophilia. One of the specialties in which Porterhouse has worked for many years is haemophilia, a disease that finds itself in a somewhat anomalous position. ... such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Freeline comprises some of the world’s leading experts in gene therapy, haemophilia and other debilitating disorders and I look forward to working closely with them to demonstrate the potential of ... She has also worked at Novo Nordisk as senir vice

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Living with haemophilia – the power of knowledge

    Haemophilia is a genetic disorder that prevents blood from clotting [1]. It is a predominantly male disorder, with haemophilia A occurring in 1 in 5, 000 live male births [1]. ... Untreated, haemophilia can be extremely debilitating, making everyday

  • Attracting doctors to low-demand specialties: A role for industry?

    Haemophilia  .  One of the specialties in which Porterhouse has worked for many years is haemophilia, a disease that finds itself in a somewhat anomalous position. ... such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or

  • Take a walk on the wild side!

    Say Comms Haemophilia Walk-a-Thon . What is this about a walk on the wild side? ... Sunday 17th April is World Haemophilia Day a very important day for the blood disorder community around the world.

  • Say Communications

    The Say Comms team are raising money for The Haemophilia Society with a walk-a-thon sponsor them here http://bit.ly/1MtvDO8. ... England is out of the 2015 rugby world cup, but is your health a winner?

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics